How Global Medtech Trends Are Reshaping South Asia's Healthcare Economy

Executive Summary

The global medical technology (medtech) landscape is undergoing seismic shifts, from aggressive pricing reforms in China to the rise of outpatient care, supply chain diversification, and the transformative impact of GLP-1 therapies. These trends, highlighted in Clarivate's "Medtech Trends to Watch in 2026," are not isolated to developed markets. They carry profound implications for South Asia—a region grappling with expanding healthcare needs, rising chronic disease burdens, and growing ambitions to become a global manufacturing hub. This article analyzes each trend through a South Asian lens, exploring how they affect regional economies, healthcare systems, and investment opportunities.

Introduction

South Asia's healthcare economy is at a crossroads. With over 1.9 billion people, rapid urbanization, and a rising middle class, demand for modern medical technologies is surging. Yet the region also faces unique challenges: affordability constraints, fragmented healthcare infrastructure, and uneven access across rural-urban divides. Meanwhile, global medtech dynamics are evolving at breakneck speed, driven by policy changes, technological breakthroughs, and shifting patient behaviors. Understanding these global currents is essential for regional stakeholders—from policymakers designing procurement strategies to multinational corporations seeking growth in emerging markets.

Clarivate's latest report identifies five key medtech trends reshaping the industry: China's expanding volume-based procurement (VBP) program, the migration of procedures to outpatient settings, supply chain pressures, the GLP-1 receptor agonist revolution, and the rise of platform-based competition through enabling technologies. This article contextualizes these trends for South Asia, assessing their potential impacts and strategic implications.

Main Analysis

1. China's VBP Expansion and the New Pricing Paradigm

China's national volume-based procurement program has evolved from a narrow cost-cutting measure into a powerful market-structuring tool. The latest VBP rounds feature sophisticated anchor-price logic, deeper price compressions, and allocation systems favoring domestic manufacturers. The effects are already rippling beyond China's borders. For South Asia, this trend is doubly consequential.

First, VBP serves as a reference benchmark for pricing negotiations in neighboring countries. Regional governments, eager to expand access to medical devices without ballooning healthcare budgets, are likely to emulate China's playbook. India's own procurement agency, HLL Lifecare, has historically used price benchmarking; the VBP model could inspire more aggressive volume-for-price deals in public health programs across the region.

Second, multinational medtech companies facing margin erosion in China are reassessing their global portfolios. Some are seeking growth avenues in emerging markets like South Asia, while others may exit commoditized product lines. This could lead to a two-tier market: premium, cutting-edge devices for well-funded private hospitals, and cost-effective, high-volume products for public health systems. Local manufacturers in India, which already produce 50–60% of the country's medical devices, stand to gain as global firms outsource production.

2. Outpatient and Ambulatory Care: A Quiet Revolution

In the United States, regulatory changes have accelerated the shift of procedures from hospitals to ambulatory surgical centers (ASCs). The CMS 2026 Final Rule expanded the ASC-covered procedures list, enabling higher-acuity operations like cardiac ablation to move to lower-cost settings. South Asia is witnessing a similar, albeit organic, transformation.

The region's private healthcare providers, particularly in India, are scaling up day-care surgery centers. The Indian government's Ayushman Bharat scheme, which promotes primary and secondary care, is also pushing less complex procedures to outpatient settings. This decentralization aligns with patient preferences for shorter hospital stays and lower out-of-pocket expenses. For device manufacturers, this shift demands innovative commercial models. Products must now be designed for ease of use, shorter procedure times, and cost efficiency. Companies that adapt their value propositions to the outpatient setting—targeting safety, efficiency, and reimbursement—will gain a competitive edge.

3. Supply Chain Pressures and the South Asian Manufacturing Opportunity

Global medtech supply chains are under strain from tariffs, geopolitics, and material costs. In response, large manufacturers are diversifying sourcing and seeking multi-region footprints. South Asia, with its cost-competitive labor force, improving infrastructure, and policy support, is emerging as a viable alternative.

India's Production-Linked Incentive (PLI) scheme for medical devices is already attracting investment. The government aims to bring 25–30% of the world's medical devices manufacturing to India by 2030. Bangladesh and Sri Lanka are also exploring medical device production as part of their export diversification strategies. The global trend of "China+1" supply chain strategies could redraw the manufacturing map, positioning South Asia as a critical link in the medtech supply chain. This aligns with the region's broader economic development goals of moving up the value chain and creating skilled employment.

4. GLP-1 Therapies and the Metabolic Disease Shift

The explosive adoption of GLP-1 receptor agonists, such as semaglutide, is transforming the management of obesity and type 2 diabetes. South Asia is at the epicenter of this metabolic epidemic—India alone has over 100 million people with diabetes, and the region has one of the highest burdens of cardiovascular disease. While GLP-1 drugs offer a promising non-surgical option for weight loss, their impact extends far beyond pharmacology.

Bariatric surgery volumes are already being affected in developed markets, and this trend will reach South Asia as drug prices drop and access improves. For medtech companies, this means recalibrating forecasts for bariatric devices, metabolic monitoring equipment, and associated diagnostic tools. More importantly, GLP-1s could shift the clinical pathway for chronic disease management, from surgical intervention to long-term medical therapy. This has implications for diabetes care devices like continuous glucose monitors and insulin pumps, as patients may manage their conditions differently. South Asian healthcare systems must prepare for this paradigm shift, integrating new pharmacological approaches with digital health tools.

5. Platform-Based Competition and Enabling Technologies

The medtech industry is moving from standalone devices to integrated platforms that combine robotics, imaging, navigation, and digital workflows. This trend is central to surgical innovation, enabling greater precision and data-driven decision-making. In South Asia, uptake is uneven: leading private hospitals in India's metros are adopting surgical robots and AI-assisted diagnostics, while public hospitals in rural areas lag far behind.

The platform shift creates both challenges and opportunities. For regional start-ups, there is a chance to build "leapfrog" technologies tailored to South Asian needs—for example, low-cost, portable imaging devices or AI algorithms that work with basic infrastructure. International companies, meanwhile, see South Asia as a fertile ground for scalable, cost-effective platform solutions. Investment in digital health infrastructure, including telemedicine and electronic medical records, is laying the groundwork for platform-based care delivery. The next few years will see intense competition to own the clinical workflow, with implications for patient outcomes and market share.

Regional Impact

The medtech trends outlined above will shape South Asia's healthcare economy in several ways:

• Economic growth: Expansion of medical device manufacturing and services can contribute to GDP and export earnings, particularly if countries capitalize on supply chain shifts.
• Regional competitiveness: Countries like India, Bangladesh, and Sri Lanka can compete for global investment in medtech R&D and manufacturing.
• Industrial development: New opportunities in device manufacturing, add-on services, and digital health.
• Trade integration: Greater regional value chains and intra-regional trade in medical goods.
• Foreign investment: Multinationals may increase investment in South Asian facilities; private equity and venture capital interest in regional medtech is growing.
• Technology adoption: Platform and digital technologies could accelerate healthcare transformation, but uneven adoption might exacerbate inequalities.
• Supply chain resilience: Localizing production boosts regional security and reduces dependence on external sources.
• Innovation ecosystems: Start-ups and research institutions could drive local innovation, but need supportive funding and regulatory frameworks.
• Employment: Manufacturing and digital health sectors can create jobs, especially in skilled professional roles.
• Infrastructure: The shift to outpatient care and digital platforms requires upgraded facilities and connectivity.
• Financial inclusion: Lower-cost devices and efficient care models can improve access for underserved populations.

Strategic Insights

For businesses: Medtech companies must adopt a nuanced South Asia strategy. High-volume, affordable products will thrive in government procurement and public health markets, while premium platforms will find customers in private tertiary hospitals. Investment in local partnerships, regulatory insight, and service-based models is essential. The outpatient shift calls for user-friendly devices and training programs for small clinics.

For investors: The supply chain reconfiguration and the rise of platform technologies open new investment themes. Look for companies with strong IP, local manufacturing capabilities, and digital health integration. Due diligence should assess policy risks, reimbursement environments, and infrastructure readiness.

For policymakers: The VBP model in China offers lessons for South Asian governments seeking to expand access sustainably. However, careful implementation is needed to avoid stifling innovation. Policymakers can support local manufacturing with incentives and better regulation, while fostering innovation ecosystems that bridge research and clinical application. Regional cooperation on standards, procurement, and data governance would amplify benefits.

For regional cooperation: SAARC and BIMSTEC platforms can facilitate information sharing and collective procurement. A unified regulatory framework for medical devices could attract investment and reduce fragmentation.

Future Outlook (3–5 Years)

Over the next half-decade, South Asia is poised to become more central to the global medtech industry. Manufacturing will expand, driven by PLI schemes and the "China+1" phenomenon. India is likely to emerge as a major export hub for medical devices, with other countries carving out niches. The adoption of platform technologies will accelerate as cloud infrastructure and AI become more accessible, but a digital divide may persist. GLP-1 availability will increase in the region, potentially reshaping demand for surgical and monitoring devices. Outpatient care will become the norm for many procedures, creating a vigorous market for ambulatory equipment. Overall, South Asia's healthcare economy will grow at double-digit rates, but challenges related to affordability, regulation, and equitable access must be addressed to ensure inclusive progress.

Conclusion

The global medtech trends to watch in 2026 are not distant phenomena—they are actively reshaping South Asia's healthcare economy. From pricing pressures to supply chain shifts, from metabolic disease management to platform-based innovation, these forces create both challenges for regional health systems and unprecedented opportunities for businesses, investors, and policymakers. By understanding these trends and shaping their own strategies, South Asian stakeholders can turn medtech transformation into a driver of economic development, regional cooperation, and improved public health. The decisions made today will determine whether the region becomes an active participant in the global medtech revolution or a passive recipient of its outcomes.

Key Takeaways

• China's VBP program will influence pricing and procurement in South Asia, creating opportunities for local manufacturers.
• The shift to outpatient and ambulatory care is accelerating in the region, requiring tailored medical device solutions.
• Supply chain diversification is opening manufacturing opportunities in India, Bangladesh, and other South Asian countries.
• GLP-1 therapies are likely to reshape the management of diabetes and obesity, affecting demand for bariatric procedures and related devices.
• Platform-based competition will drive technology adoption but requires investments in digital infrastructure.

SEO Keywords

South Asia Economy, Medtech Trends, Healthcare Investment, Medical Devices, Volume-Based Procurement, Ambulatory Surgery, Supply Chain, GLP-1, Platform Technologies, South Asia Health, Digital Health, Manufacturing

Sources

• Clarivate. "5 Medtech Trends to Watch in 2026." https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026